Skin appendages and related diseases, corneal and ocular surface diseases, systemic disease ocular manifestations
Conditions
Interventions
Atopic dermatitis with ocular symptoms and signs:None
Atopic dermatitis without ocular symptoms and signs:None
Seborrheic dermatitis with ocular symptoms and signs:None
Seborrheic dermatitis without ocular symptoms and signs:None
Rosacea with ocular symptoms and signs:None
Rosacea without ocular symptoms and signs:None
MGD related blepharitis without dermatosis:None
Sponsors
Beijing Tongren Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in this clinical study and sign informed consent. 2. No gender limitation, age >=18 years old. 3. The dermatological group should meet the diagnostic criteria for specific skin diseases. 4. The ocular surface disease group should meet the diagnostic criteria for specific ocular surface diseases.
Exclusion criteria
Exclusion criteria: 1. Systemic use within 3 months, treatment with antibiotics, anti-parasitic or anti-inflammatory steroids within and outside 2 weeks; 2. accompanied by infectious eye inflammation; 3. facial infectious skin diseases; 4. Patients with other systemic diseases not suitable for inclusion (such as definite digestive tract diseases (such as IBD), autoimmune diseases, tumors, uncontrolled hypertension and diabetes, etc.); 5. Pregnant and lactating women; 6. other medications for skin diseases are currently being used; 7. Patients who smoked within 3 months and drank alcohol within 1 week (except patients with chronic alcoholism) 8. Patients who have not signed informed consent; 9. Obvious abnormalities in slit lamp microscopy and/or researchers' judgment that may affect the evaluation of indicators related to ocular surface diseases, including eye trauma and history of eye trauma, and abnormal anatomical structure of the eyelid; 10. had topical eye treatment with tea tree oil, okra eye patch, or hypochlorous acid within 2 weeks, or were unwilling to give up these treatments during the study period; 11. had received intense pulsed light (IPL) therapy, such as optimized Pulse Technology (OPT) or Emphasis Section Pulsed Light (IRPL), for 2 weeks, or were unwilling to forgo these treatments for the duration of the study; 12. have used artificial eyelashes, eyelash lengthening or other cosmetic eyelash or eyelid surgery (e.g., eyeliner, eyelash dyeing, eyelash curling, etc.) within 1 week, or are unwilling to give up use during the study period; 13. Ocular or periocular malignancy; 14. Active allergies or infections (bacterial, viral or fungal), including fever; 15. are likely or in circumstances (including language barriers) that the investigator believes may expose the subject to significant risk, confuse the results of the trial, or may significantly interfere with the subject's participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid metabolomics analysis;16s sequencing; | — |
Countries
China
Contacts
Public ContactYing Jie
Beijing Tongren Hospital, Capital Medical University
Outcome results
None listed